Study of immune antibodies after first-time EBV infection
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Infections, Skin clinical trials.
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent to take part in the study
- For the EBV (infectious mononucleosis) group: a clinician confirms your first-time EBV infection
- You have symptom and blood test signs that fit infectious mononucleosis or a similar EBV illness
- Your EBV blood test pattern should match primary infection (specific antibody results like EBNA IgG negative and VCA IgM positive)
- You should not have a weakened immune system or take strong immune-suppressing medicines (like prednisone at ≥10 mg/day equivalent)
- You should not have a known autoimmune disease (like lupus or vasculitis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether people with multiple sclerosis (MS) in Egypt have higher levels of antibodies (proteins that fight infection) to the Epstein-Barr virus (EBV, a common virus that causes mono) compared to healthy people. The goal is to learn more about the possible link between EBV and MS, which might help with future understanding or treatment.
This study tracks health outcomes over time in people who have a high level of the EBV virus in their blood. It may help researchers understand what happens in chronic (long-lasting) EBV infection and which outcomes to watch for.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
This study tests two experimental vaccines (V350A and V350B) designed to prevent Epstein-Barr virus infection. It is looking for healthy adolescents and adults to see if the vaccines are safe and produce a good immune response.
This research study looks for genetic factors that may explain why some people develop severe, long-lasting Epstein-Barr virus (EBV) infection. Researchers will study blood and tissue samples from patients with this rare condition, their healthy relatives, and unrelated volunteers to understand the disease better.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
Hear when a new Epstein-Barr Virus (EBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.